Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
This article was originally published in The Tan Sheet
Executive Summary
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits